Smallpox and Vaccinia The Diseases Behind the Policy - PowerPoint PPT Presentation

1 / 49
About This Presentation
Title:

Smallpox and Vaccinia The Diseases Behind the Policy

Description:

Smallpox and Vaccinia The Diseases Behind the Policy – PowerPoint PPT presentation

Number of Views:68
Avg rating:3.0/5.0
Slides: 50
Provided by: jen93
Category:

less

Transcript and Presenter's Notes

Title: Smallpox and Vaccinia The Diseases Behind the Policy


1
Smallpox and VacciniaThe Diseases Behind the
Policy
  • Jeffrey Engel, MD
  • NC State Epidemiologist
  • General Communicable Disease Control

2
Smallpox Eradicated 1977Last Case in US in 1950s
3
Smallpox A Clinical Diagnosis
Henderson JAMA 281199921-27
4
(No Transcript)
5

6
(No Transcript)
7
(No Transcript)
8
Smallpox
  • History
  • Unique human pathogen
  • 1157 BC, mummy of Ramses V
  • 15th Century called Small pox to differentiate it
    from the Great Pox
  • Variola Major
  • CFR 30
  • Last case in Bangladesh 1975
  • Variola Minor
  • CFR
  • Last case in Somalia 1977

9
Smallpox
  • Variola
  • Family Poxviridae
  • Genus Orthopox
  • Large DS DNA viruses
  • Replicate in cytoplasm
  • Other poxviruses
  • Vaccinia (origin unknown)
  • Cow pox (Jenner vaccine)
  • Monkey pox

10
Smallpox
  • Pathogenesis of serious manifestations is due to
    overwhelming viremia and host response
  • Four Clinical Forms
  • Ordinary
  • Modified (vaccinated)
  • Flat (5-10 in children, CFR 50)
  • Hemorrhagic (2 in adults, CFR 60)

11
Differential Diagnosis
  • Smallpox
  • severe prodrome
  • centrifugal rash
  • firm lesions
  • slow progression to scabs in 2-3 weeks
  • synchronous lesions
  • respiratory and fomite spread
  • Chickenpox
  • mild prodrome
  • centripetal rash
  • soft lesions
  • progresses to scabs in
  • lesions in various stages
  • respiratory spread

12
Smallpox Diagnosis
  • Appearance of rash
  • Hemorrhagic smallpox may be mistaken for
    meningococcemia or severe acute leukemia
  • Viral Detection
  • Culture, molecular (PCR), visual (EM)
  • Specimen should be obtained by immunized person
    place in vacutainer tube, tape juncture of
    stopper and tube, place in second durable,
    watertight container
  • Alert lab
  • Rule in Varicella
  • Tsanck prep (multinucleated giant cells)
  • DFA for varicella

13
Reality
  • 26 year-old Israeli man presented to Mercy Main
    Hospital ED in Charlotte on November 6 with a
    vesicular rash
  • Not ill, afebrile
  • arrived US 9 days ago in Newark, NJ
  • travel to Disney World
  • in Charlotte on business
  • ED doc benign rash, IC Nurse what about
    smallpox?
  • Mercy Main notifies RST-7 Dr. Steve Keener
  • Dr. Keener calls Dr. Engel
  • Dr. Engel notifies NCHAN, Dr. Kirkpatrick
    acknowledges
  • Patient isolated, digital photos taken, emailed
    to State and CDC

14
(No Transcript)
15
Reality Aftermath
  • ID consult insect bites
  • No vesicular fluid for DFA
  • State and CDC benign rash
  • FBI background check clear
  • Patient discharged 4 hours later
  • How would your facility have handled this case?

16
Smallpox Epidemiology
  • Relatively long incubation period (12-14 days)
  • Slow person-to-person spread from infectious
    cases, usually
  • Cases infectious only during rash, infectivity
    drops sharply after week 1
  • Inapparent infections extremely rare, not
    infectious
  • Permanent immunity usually follows recovery from
    the disease
  • No known effective treatment

17
Smallpox Epidemiology
  • A focal disease of only moderate communicability
  • Infectious cases comprise only a fraction of the
    population of an infected community
  • Only a fraction of communities in an infected
    country contain infectious cases at any one time
  • The only persons at risk of acquiring smallpox
    are those susceptible individuals in actual
    physical contact with active cases or their
    fomites
  • There are no other hosts (reservoir) and there is
    no carrier state
  • Hence the strategy Surveillance (find the active
    cases) and Containment (ring vaccination)

18
Smallpox Control
  • Vaccinate all persons in the identified
    communities, maintain forced isolation for 2
    incubation periods (1 month) after last onset
    date
  • nobody gets in without a vaccination
  • nobody gets out if they have a rash

19
(No Transcript)
20
Vaccinia Facts
  • An effective immunogen against smallpox
  • routinely possible to abort an incubating
    infection in an exposed individual if vaccination
    is given within 4 to 5 days after exposure
  • immunity induced in only 7-10 days in persons
    never previously vaccinated
  • in fewer days in persons with past vaccination
  • under tropical field conditions, 95 of
    vaccinees were completely protected for a minimum
    of 1 year after a single dose

21
Vaccinia Ring and Eradication
  • Each time an active case is surrounded by a ring
    of freshly immunized people, a potential chain of
    infection is broken
  • When ring vaccination is pursued at a faster rate
    than the natural transmission rate, the incidence
    of smallpox declines
  • Eradication occurs when the last case is
    surrounded, and the chain of infection is
    interrupted

22
The Basics of Smallpox Eradication
  • Surveillance to find the cases
  • and
  • Containment to interrupt transmission

23
Rahima Banu ...a 3 year old girl from Kuralia
village, Bhola Island, Bangladesh onset 16 Oct
75 The last natural case of variola major in the
world. photo by Pierre Claquin
24
Smallpox Vaccine
  • Discontinued in US in 1972
  • Waning immunity
  • up to 5 years
  • 10 years revaccination recommended
  • Most vaccinees will get modified disease

CFR ()
Years since vaccination
25
Smallpox Transmission
  • Droplet Aerosol
  • During first several days of rash
  • Exposure within 6 feet
  • Airborne (Rare)
  • Beyond 6 feet
  • Indoor air ventilation
  • Fomite
  • Until scabs fall off

26
Hospital Infection Control
  • Plan for Scenarios
  • Suspect case in ED
  • Inpatient admitted with febrile illness
  • General ward
  • ICU
  • Coordination
  • Infection Control, Disaster Planning
  • Administration, Hospital Board

27
Hospital Infection Control
  • No plan to designate a NC smallpox hospital in
    the event of a large outbreak
  • Be prepared to cohort locally
  • Type C unit smallpox cases
  • Type X unit unknown febrile illness in a contact
  • incubating smallpox
  • vaccine reaction
  • other cause
  • Type R unit asymptomatic contact

28
Hospital Infection Control
  • Suspect Case in ED
  • Know who to call (Hospital IC, LHD, RST, State,
    CDC)
  • NC Health Alert Network
  • Isolate patient in Airborne and Contact
    Precautions
  • negative pressure room, outside exhaust
  • N-95, fit-tested respirator mask
  • gowns, gloves, and eye protection
  • Record names and contact info of those in ED

29
Hospital Infection Control
  • Suspect Case in ED
  • Obtain expert consultation emergently
  • Dermatologist, ID
  • Obtain digital photos of rash and email to
    authorities
  • Rule in varicella with Tzanck and DFA of
    vesicle scraping/fluid (tests should be available
    locally)

30
ACIP of CDC, June 2002Recommendation to
DHHSPre-Event Smallpox Vaccination
  • Vaccinate those persons, as designated by the
    appropriate bioterrorism and public health
    authorities, who will conduct initial
    investigation and follow-up of initial smallpox
    cases that would necessitate direct patient
    contact, and
  • Vaccinate healthcare personnel at risk for
    exposure to the initial smallpox cases that are
    pre-designated to receive these cases.

31
SMALLPOX
VACCINATION METHOD
32
VACCINATION METHOD
Multiple puncture vaccination Bifurcated needle
(single use) Discard in Biohazard container
Never dip needle into vial more than once
33
VACCINATION METHOD
Preferred site is the Deltoid Area on Upper Arm
34
VACCINATION METHOD
Step 1
Skin Preparation
NO skin preparation is required!
DO NOT use alcohol under any circumstances Alcohol
will inactivate the vaccine
Soap and water may be used to clean visible dirt
from skin
35
VACCINATION METHOD
Step 2
Dip Needle
The needle is dipped once into the vaccine vial
and withdrawn.
36
VACCINATION METHOD
Step 3
Rest wrist on arm of patient
Make 15 perpendicular skin insertions within a
5mm area
Use enough force to see a trace of blood at the
site
Discard needle immediately
37
VACCINATION METHOD
Step 4
Absorb excess vaccine on gauze pad
Immediately discard gauze in a Biohazard
container
38
VACCINATION METHOD
Step 5
Cover Vaccination Site
The site must be covered to prevent spread of
the virus
Use sterile gauze pad and tape Semi permeable
occlusive dressing OK
39
VACCINATION METHOD
Step 6
Caution Vaccinee
Contact transmission of the virus is possible DO
NOT rub or scratch the site CAREFULLY discard
bandage WASH hands after handling bandage or site
40
VACCINATION METHOD
41
EVOLVING PRIMARY VACCINATION
42
Risks Complications of Vaccination U.S., 1968
CDC
Henderson D, et al. JAMA 28119992127-2137
43
Vaccine Adverse Events
44
Contraindications(Pre-Event)
  • Allergic to vaccine components
  • Pregnant
  • Age
  • Immunosuppressed including HIV antibody positive
  • Eczema or other chronic skin disease
  • Liver or kidney disease
  • Recent (60 days) vaccination with live attenuated
    virus
  • Recent (6 months) blood transfusion
  • Household or occupational contact with person
    with risk factors

45
Contraindications(Post-Exposure)
  • NONE

46
Management of AEs
  • Vaccinia Immune Globulin (VIG)
  • production is being ramped-up
  • controlled by CDC, IND status
  • Indicated in eczema vaccinatum, progressive
    vaccinia
  • Cidofovir
  • FDA approved antiviral for CMV disease
  • IND status (off-label use) for vaccinia

47
Vaccination Issues
  • Voluntary
  • Manpower issues
  • 30 out-of-work from day 7-10 because of
    symptoms stagger vaccination schedule
  • Workmans Comp Vs. sick leave
  • Liability
  • Homeland Security bill signed into law 11/25/02
    by President Bush
  • Federal protection if HHS Secretary declares an
    emergency

48
Vaccine Infection Control Issues
  • Vaccinia is a communicable disease
  • Direct contact
  • Rare reports of HCW to patient transmission
  • HICPAC no furlough necessary
  • viral shedding for 19 days
  • cover site with gauze and transparent
    semi-permeable dressing and clothing
  • reassign for 2 weeks if caring for
    immunosuppressed patients

49
Pre-Event Vaccination
  • Who Public Health Disease Investigators,
    Healthcare Teams
  • What Undiluted Dryvax (relicensed by FDA early
    November)
  • When early 2003
  • Where LHD, Occupational Health
  • Why Political decision
Write a Comment
User Comments (0)
About PowerShow.com